Apremilast probably has an early but limited role to play in patients with psoriatic arthritis largely due to its safety and ease of use. The PALACE 4 study of apremilast (20 or 30mg) versus placebo found the oral phosphodiesterase 4 inhibitor achieved response rates of about 30% in DMARD- and biologic-naive patients. At week 16, ...
Early but modest benefit from apremilast in PsA
By Mardi Chapman
24 Apr 2018